CD63 and breast adenocarcinoma: The design was validated by biofunctionalizing the nanosensors with anti-CD63 antibodies targeted towards the tetraspanin CD63 membrane bound proteins present in exosomes secreted by MCF7 breast adenocarcinoma cells.